UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes

Nature reviews. Urology, 2020-05, Vol.17 (5), p.259-270

2020

Volltextzugriff (PDF)

Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade

Oncotarget, 2017-08, Vol.8 (34), p.56051-56065

2017

Volltextzugriff (PDF)

The prognostic significance of Gleason scores in metastatic prostate cancer

Urologic oncology, 2014-07, Vol.32 (5), p.707-713

2014

Volltextzugriff (PDF)

The Epidemiological, Mechanistic and Potential Clinical Role of Androgen Receptor (AR) in Urothelial Carcinoma

Current drug targets, 2016-02, Vol.17 (2), p.196-205

2016

Volltextzugriff (PDF)

Detection of Circulating Tumor Cells in Metastatic and Clinically Localized Urothelial Carcinoma

Urology (Ridgewood, N.J.), 2011-10, Vol.78 (4), p.863-867

2011

Volltextzugriff (PDF)

Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study

Journal of clinical oncology, 2011-05, Vol.29 (15), p.2040-2045

2011

Volltextzugriff (PDF)

Patient characterization and usage trends of proton beam therapy for localized prostate cancer in the United States: A study of the National Cancer Database

Urologic oncology, 2017-06, Vol.35 (6), p.438-446

2017

Volltextzugriff (PDF)

Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer

Journal of clinical oncology, 2023-01, Vol.41 (1), p.22-31

2023

Volltextzugriff (PDF)

Simultaneous activation of Kras and inactivation of p53 induces soft tissue sarcoma and bladder urothelial hyperplasia

PloS one, 2013-09, Vol.8 (9), p.e74809

2013

Volltextzugriff (PDF)

Challenges in the Diagnosis of Urothelial Carcinoma Variants: Can Emerging Molecular Data Complement Pathology Review?

Urology (Ridgewood, N.J.), 2017-04, Vol.102, p.7-16

2017

Volltextzugriff (PDF)

EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

Journal of clinical oncology, 2020-04, Vol.38 (10), p.1041-1049

2020

Volltextzugriff (PDF)

Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer

Journal of clinical oncology, 2016-08, Vol.34 (24), p.2835-2842

2016

Volltextzugriff (PDF)

Gleason stratifications prognostic for survival in men receiving definitive external beam radiation therapy for localized prostate cancer

Urologic oncology, 2015-02, Vol.33 (2), p.71.e11-71.e19

2015

Volltextzugriff (PDF)

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer

Journal of clinical oncology, 2019-05, Vol.37 (13), p.1051-1061

2019

Volltextzugriff (PDF)

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

The lancet oncology, 2015-02, Vol.16 (2), p.152-160

2015

Volltextzugriff (PDF)

Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer

Life (Basel, Switzerland), 2021-08, Vol.11 (9), p.884

2021

Volltextzugriff (PDF)

Micropapillary bladder cancer: Current treatment patterns and review of the literature

Urologic oncology, 2014-08, Vol.32 (6), p.826-832

2014

Volltextzugriff (PDF)

Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma

Journal of clinical oncology, 2014-09, Vol.32 (25), p.2765-2772

2014

Volltextzugriff (PDF)

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

The New England journal of medicine, 2012-09, Vol.367 (13), p.1187-1197

2012

Volltextzugriff (PDF)

The Changing Treatment Landscape for Metastatic Urothelial Carcinoma

Journal of the National Comprehensive Cancer Network, 2018-05, Vol.16 (5S), p.636-638

Flaig, Thomas W.

2018

Volltextzugriff (PDF)

Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

Journal of clinical oncology, 2023-09, Vol.41 (25), p.4107-4117

2023

Volltextzugriff (PDF)

Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer

Integrative cancer therapies, 2018-12, Vol.17 (4), p.1103-1108

2018

Volltextzugriff (PDF)

Low-dose diethylstilbestrol for the treatment of advanced prostate cancer

Urologic oncology, 2013-02, Vol.31 (2), p.198-204

2013

Volltextzugriff (PDF)

1 – 25 von 251

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(235)
Mit Volltextzugriff
(204)

Publikationsform

Sprache

Englisch
(249)
Deutsch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(120)
Life Sciences & Biomedicine
(117)
Humans
(104)
Oncology
(83)
Male
(75)
Aged
(43)
Urology & Nephrology
(38)
Middle Aged
(35)
Prostate Cancer
(29)
Female
(26)
Urology
(25)
Prostatic Neoplasms - Drug Therapy
(24)
Treatment Outcome
(23)
Biological And Medical Sciences
(21)
Medical Sciences
(21)
Adult
(20)
Chemotherapy
(20)
Care And Treatment
(19)
Aged, 80 And Over
(17)
Antineoplastic Agents - Therapeutic Use
(17)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes

Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade

The prognostic significance of Gleason scores in metastatic prostate cancer

The Epidemiological, Mechanistic and Potential Clinical Role of Androgen Receptor (AR) in Urothelial Carcinoma

Detection of Circulating Tumor Cells in Metastatic and Clinically Localized Urothelial Carcinoma

Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study

Patient characterization and usage trends of proton beam therapy for localized prostate cancer in the United States: A study of the National Cancer Database

Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer

Simultaneous activation of Kras and inactivation of p53 induces soft tissue sarcoma and bladder urothelial hyperplasia

Challenges in the Diagnosis of Urothelial Carcinoma Variants: Can Emerging Molecular Data Complement Pathology Review?

EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer

Gleason stratifications prognostic for survival in men receiving definitive external beam radiation therapy for localized prostate cancer

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer

Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer

Micropapillary bladder cancer: Current treatment patterns and review of the literature

Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

The Changing Treatment Landscape for Metastatic Urothelial Carcinoma

Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer

TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer

Low-dose diethylstilbestrol for the treatment of advanced prostate cancer

Suchergebnisse filtern